Your browser doesn't support javascript.
loading
Determining meaningful health-related quality-of-life improvement in persons with haemophilia A using the Haemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL).
von Mackensen, Sylvia; Catalani, Olivier; Asikanius, Elina; Paz-Priel, Ido; Lehle, Michaela; Trask, Peter.
Afiliación
  • von Mackensen S; Department of Medical Psychology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
  • Catalani O; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Asikanius E; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Paz-Priel I; Genentech, Inc, South San Francisco, CA, USA.
  • Lehle M; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Trask P; Genentech, Inc, South San Francisco, CA, USA.
Haemophilia ; 26(6): 1019-1030, 2020 Nov.
Article en En | MEDLINE | ID: mdl-33084166
INTRODUCTION: The Haem-A-QoL is frequently utilized in haemophilia clinical trials and captures relevant aspects of disease impact. Thresholds for some domains 'Physical Health' (PH), 'Sports & Leisure' (S&L) and 'Total Score' (TS) have previously been identified to benchmark the amount of change that is meaningful to patients, but not been independently confirmed. AIM: The objective of this analysis was to determine the clinically important responder (CIR) thresholds for these three domains. METHODS: CIR thresholds in adult persons with haemophilia A (PwHA) enrolled in HAVEN 1, 3 and 4 studies were determined for improvements from baseline to 24 weeks of emicizumab prophylaxis using anchor-based methodology with the EQ-5D-5L as the validated anchor, cumulative distribution functions (CDF) and distribution-based methodology. The results were compared with previously published thresholds. RESULTS: At baseline and after 24 weeks of emicizumab prophylaxis, Haem-A-QoL data from 241/258 patients were available. Concordance was observed between the Haem-A-QoL and EQ-5D-5L in patterns of improvement, deterioration or lack of change. CDF estimates of the Haem-A-QoL PH and TS grouped by response categories on the Mobility, Pain/Discomfort and Usual Activities EQ-5D-5L domains demonstrated the same pattern of responses to each scale; distribution-based estimates were 11.9 for PH, 13.9 for S&L, and 8.3 for TS. CONCLUSION: Our responder thresholds are mostly consistent with those proposed by Wyrwich et al (cut-offs of -10 and -7 for PH and TS, respectively). The majority of responders to emicizumab prophylaxis had improvements greater than the previously reported 10-point reduction in PH and 7-point reduction in TS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Hemofilia A Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Calidad de Vida / Hemofilia A Tipo de estudio: Clinical_trials / Prognostic_studies / Qualitative_research Aspecto: Patient_preference Límite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Haemophilia Asunto de la revista: HEMATOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido